Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Complexes formed by mutant p53 and their roles in breast cancer.

Bellazzo A, Sicari D, Valentino E, Del Sal G, Collavin L.

Breast Cancer (Dove Med Press). 2018 Jun 18;10:101-112. doi: 10.2147/BCTT.S145826. eCollection 2018. Review.

2.

GDA, a web-based tool for Genomics and Drugs integrated analysis.

Caroli J, Sorrentino G, Forcato M, Del Sal G, Bicciato S.

Nucleic Acids Res. 2018 Jul 2;46(W1):W148-W156. doi: 10.1093/nar/gky434.

3.

Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells.

Lisek K, Campaner E, Ciani Y, Walerych D, Del Sal G.

Oncotarget. 2018 Apr 17;9(29):20508-20523. doi: 10.18632/oncotarget.24974. eCollection 2018 Apr 17.

4.

Cell-autonomous and cell non-autonomous downregulation of tumor suppressor DAB2IP by microRNA-149-3p promotes aggressiveness of cancer cells.

Bellazzo A, Di Minin G, Valentino E, Sicari D, Torre D, Marchionni L, Serpi F, Stadler MB, Taverna D, Zuccolotto G, Montagner IM, Rosato A, Tonon F, Zennaro C, Agostinis C, Bulla R, Mano M, Del Sal G, Collavin L.

Cell Death Differ. 2018 Jul;25(7):1224-1238. doi: 10.1038/s41418-018-0088-5. Epub 2018 Mar 22.

PMID:
29568059
5.

The stiff RhoAd from mevalonate to mutant p53.

Sorrentino G, Mantovani F, Del Sal G.

Cell Death Differ. 2018 Mar;25(4):643-645. doi: 10.1038/s41418-018-0091-x. Epub 2018 Mar 6. No abstract available.

PMID:
29511341
6.

MiR-181 family-specific behavior in different cancers: a meta-analysis view.

Pop-Bica C, Pintea S, Cojocneanu-Petric R, Del Sal G, Piazza S, Wu ZH, Alencar AJ, Lossos IS, Berindan-Neagoe I, Calin GA.

Cancer Metastasis Rev. 2018 Mar;37(1):17-32. doi: 10.1007/s10555-017-9714-9.

PMID:
29327093
7.

Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis.

Ingallina E, Sorrentino G, Bertolio R, Lisek K, Zannini A, Azzolin L, Severino LU, Scaini D, Mano M, Mantovani F, Rosato A, Bicciato S, Piccolo S, Del Sal G.

Nat Cell Biol. 2018 Jan;20(1):28-35. doi: 10.1038/s41556-017-0009-8. Epub 2017 Dec 18.

8.

Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding.

Liao P, Zeng SX, Zhou X, Chen T, Zhou F, Cao B, Jung JH, Del Sal G, Luo S, Lu H.

Mol Cell. 2017 Dec 21;68(6):1134-1146.e6. doi: 10.1016/j.molcel.2017.11.006. Epub 2017 Dec 7.

PMID:
29225033
9.

Bridge-Induced Translocation between NUP145 and TOP2 Yeast Genes Models the Genetic Fusion between the Human Orthologs Associated With Acute Myeloid Leukemia.

Tosato V, West N, Zrimec J, Nikitin DV, Del Sal G, Marano R, Breitenbach M, Bruschi CV.

Front Oncol. 2017 Sep 29;7:231. doi: 10.3389/fonc.2017.00231. eCollection 2017.

10.

Dynamic landscape and regulation of RNA editing in mammals.

Tan MH, Li Q, Shanmugam R, Piskol R, Kohler J, Young AN, Liu KI, Zhang R, Ramaswami G, Ariyoshi K, Gupte A, Keegan LP, George CX, Ramu A, Huang N, Pollina EA, Leeman DS, Rustighi A, Goh YPS; GTEx Consortium; Laboratory, Data Analysis &Coordinating Center (LDACC)—Analysis Working Group; Statistical Methods groups—Analysis Working Group; Enhancing GTEx (eGTEx) groups; NIH Common Fund; NIH/NCI; NIH/NHGRI; NIH/NIMH; NIH/NIDA; Biospecimen Collection Source Site—NDRI; Biospecimen Collection Source Site—RPCI; Biospecimen Core Resource—VARI; Brain Bank Repository—University of Miami Brain Endowment Bank; Leidos Biomedical—Project Management; ELSI Study; Genome Browser Data Integration &Visualization—EBI; Genome Browser Data Integration &Visualization—UCSC Genomics Institute, University of California Santa Cruz, Chawla A, Del Sal G, Peltz G, Brunet A, Conrad DF, Samuel CE, O'Connell MA, Walkley CR, Nishikura K, Li JB.

Nature. 2017 Oct 11;550(7675):249-254. doi: 10.1038/nature24041.

11.

Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1.

Tosi A, Dalla Santa S, Cappuzzello E, Marotta C, Walerich D, Del Sal G, Zanovello P, Sommaggio R, Rosato A.

Oncoimmunology. 2017 Apr 5;6(8):e1313371. doi: 10.1080/2162402X.2017.1313371. eCollection 2017. Erratum in: Oncoimmunology. 2017 Dec 4;7(1):e1412885.

12.

Mutant p53 potentiates the oncogenic effects of insulin by inhibiting the tumor suppressor DAB2IP.

Valentino E, Bellazzo A, Di Minin G, Sicari D, Apollonio M, Scognamiglio G, Di Bonito M, Botti G, Del Sal G, Collavin L.

Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):7623-7628. doi: 10.1073/pnas.1700996114. Epub 2017 Jun 30.

13.

Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.

Noto A, De Vitis C, Pisanu ME, Roscilli G, Ricci G, Catizone A, Sorrentino G, Chianese G, Taglialatela-Scafati O, Trisciuoglio D, Del Bufalo D, Di Martile M, Di Napoli A, Ruco L, Costantini S, Jakopin Z, Budillon A, Melino G, Del Sal G, Ciliberto G, Mancini R.

Oncogene. 2017 Aug 10;36(32):4671-4672. doi: 10.1038/onc.2017.212. Epub 2017 Jun 19.

PMID:
28628115
14.

A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action.

Campaner E, Rustighi A, Zannini A, Cristiani A, Piazza S, Ciani Y, Kalid O, Golan G, Baloglu E, Shacham S, Valsasina B, Cucchi U, Pippione AC, Lolli ML, Giabbai B, Storici P, Carloni P, Rossetti G, Benvenuti F, Bello E, D'Incalci M, Cappuzzello E, Rosato A, Del Sal G.

Nat Commun. 2017 Jun 9;8:15772. doi: 10.1038/ncomms15772.

15.

Dynamic regulation of Pin1 expression and function during zebrafish development.

Ibarra MS, Borini Etichetti C, Di Benedetto C, Rosano GL, Margarit E, Del Sal G, Mione M, Girardini J.

PLoS One. 2017 Apr 20;12(4):e0175939. doi: 10.1371/journal.pone.0175939. eCollection 2017.

16.

Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.

Noto A, De Vitis C, Pisanu ME, Roscilli G, Ricci G, Catizone A, Sorrentino G, Chianese G, Taglialatela-Scafati O, Trisciuoglio D, Del Bufalo D, Di Martile M, Di Napoli A, Ruco L, Costantini S, Jakopin Z, Budillon A, Melino G, Del Sal G, Ciliberto G, Mancini R.

Oncogene. 2017 Aug 10;36(32):4573-4584. doi: 10.1038/onc.2017.75. Epub 2017 Apr 3. Erratum in: Oncogene. 2017 Jun 19;:.

PMID:
28368399
17.

Mutant p53-Nrf2 axis regulates the proteasome machinery in cancer.

Lisek K, Walerych D, Del Sal G.

Mol Cell Oncol. 2016 Sep 2;4(1):e1217967. doi: 10.1080/23723556.2016.1217967. eCollection 2017.

18.

Glucocorticoid receptor signalling activates YAP in breast cancer.

Sorrentino G, Ruggeri N, Zannini A, Ingallina E, Bertolio R, Marotta C, Neri C, Cappuzzello E, Forcato M, Rosato A, Mano M, Bicciato S, Del Sal G.

Nat Commun. 2017 Jan 19;8:14073. doi: 10.1038/ncomms14073.

19.

PIN1 in breast development and cancer: a clinical perspective.

Rustighi A, Zannini A, Campaner E, Ciani Y, Piazza S, Del Sal G.

Cell Death Differ. 2017 Feb;24(2):200-211. doi: 10.1038/cdd.2016.122. Epub 2016 Nov 11. Review.

20.

MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer.

Lo Sardo F, Forcato M, Sacconi A, Capaci V, Zanconato F, Di Agostino S, Del Sal G, Pandolfi PP, Strano S, Bicciato S, Blandino G.

Carcinogenesis. 2017 Jan;38(1):64-75. doi: 10.1093/carcin/bgw110. Epub 2016 Oct 17.

PMID:
27797825
21.

Multi-omics reveals global effects of mutant p53 gain-of-function.

Walerych D, Lisek K, Del Sal G.

Cell Cycle. 2016 Nov 16;15(22):3009-3010. Epub 2016 Jul 26. No abstract available.

22.

Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.

Walerych D, Lisek K, Sommaggio R, Piazza S, Ciani Y, Dalla E, Rajkowska K, Gaweda-Walerych K, Ingallina E, Tonelli C, Morelli MJ, Amato A, Eterno V, Zambelli A, Rosato A, Amati B, Wiśniewski JR, Del Sal G.

Nat Cell Biol. 2016 Aug;18(8):897-909. doi: 10.1038/ncb3380. Epub 2016 Jun 27.

PMID:
27347849
23.

Effects of Pin1 Loss in Hdh(Q111) Knock-in Mice.

Agostoni E, Michelazzi S, Maurutto M, Carnemolla A, Ciani Y, Vatta P, Roncaglia P, Zucchelli S, Leanza G, Mantovani F, Gustincich S, Santoro C, Piazza S, Del Sal G, Persichetti F.

Front Cell Neurosci. 2016 May 2;10:110. doi: 10.3389/fncel.2016.00110. eCollection 2016.

24.

Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex.

Garibaldi F, Falcone E, Trisciuoglio D, Colombo T, Lisek K, Walerych D, Del Sal G, Paci P, Bossi G, Piaggio G, Gurtner A.

Oncogene. 2016 Jul 21;35(29):3760-70. doi: 10.1038/onc.2016.51. Epub 2016 Mar 21.

PMID:
26996669
25.

Pin1 is required for sustained B cell proliferation upon oncogenic activation of Myc.

D'Artista L, Bisso A, Piontini A, Doni M, Verrecchia A, Kress TR, Morelli MJ, Del Sal G, Amati B, Campaner S.

Oncotarget. 2016 Apr 19;7(16):21786-98. doi: 10.18632/oncotarget.7846.

26.

Mutant p53: One, No One, and One Hundred Thousand.

Walerych D, Lisek K, Del Sal G.

Front Oncol. 2015 Dec 21;5:289. doi: 10.3389/fonc.2015.00289. eCollection 2015. Review.

27.

YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins.

Di Agostino S, Sorrentino G, Ingallina E, Valenti F, Ferraiuolo M, Bicciato S, Piazza S, Strano S, Del Sal G, Blandino G.

EMBO Rep. 2016 Feb;17(2):188-201. doi: 10.15252/embr.201540488. Epub 2015 Dec 21.

28.

MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells.

Taccioli C, Sorrentino G, Zannini A, Caroli J, Beneventano D, Anderlucci L, Lolli M, Bicciato S, Del Sal G.

Oncotarget. 2015 Nov 17;6(36):38854-65. doi: 10.18632/oncotarget.5749.

29.

Notch is a direct negative regulator of the DNA-damage response.

Vermezovic J, Adamowicz M, Santarpia L, Rustighi A, Forcato M, Lucano C, Massimiliano L, Costanzo V, Bicciato S, Del Sal G, d'Adda di Fagagna F.

Nat Struct Mol Biol. 2015 May;22(5):417-24. doi: 10.1038/nsmb.3013. Epub 2015 Apr 20.

PMID:
25895060
30.

p53 orchestrates calcium signaling in vivo.

Sorrentino G, Comel A, Del Sal G.

Cell Cycle. 2015;14(9):1343-4. doi: 10.1080/15384101.2015.1024583. No abstract available.

31.

Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells.

Farra R, Dapas B, Baiz D, Tonon F, Chiaretti S, Del Sal G, Rustighi A, Elvassore N, Pozzato G, Grassi M, Grassi G.

Biochimie. 2015 May;112:85-95. doi: 10.1016/j.biochi.2015.02.015. Epub 2015 Mar 3.

PMID:
25742740
32.

Interaction of p53 with prolyl isomerases: Healthy and unhealthy relationships.

Mantovani F, Zannini A, Rustighi A, Del Sal G.

Biochim Biophys Acta. 2015 Oct;1850(10):2048-60. doi: 10.1016/j.bbagen.2015.01.013. Epub 2015 Jan 29. Review.

PMID:
25641576
33.

p53 at the endoplasmic reticulum regulates apoptosis in a Ca2+-dependent manner.

Giorgi C, Bonora M, Sorrentino G, Missiroli S, Poletti F, Suski JM, Galindo Ramirez F, Rizzuto R, Di Virgilio F, Zito E, Pandolfi PP, Wieckowski MR, Mammano F, Del Sal G, Pinton P.

Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1779-84. doi: 10.1073/pnas.1410723112. Epub 2015 Jan 26.

34.

Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP.

Di Minin G, Bellazzo A, Dal Ferro M, Chiaruttini G, Nuzzo S, Bicciato S, Piazza S, Rami D, Bulla R, Sommaggio R, Rosato A, Del Sal G, Collavin L.

Mol Cell. 2014 Dec 4;56(5):617-29. doi: 10.1016/j.molcel.2014.10.013. Epub 2014 Nov 13.

35.

Pin1-dependent signalling negatively affects GABAergic transmission by modulating neuroligin2/gephyrin interaction.

Antonelli R, Pizzarelli R, Pedroni A, Fritschy JM, Del Sal G, Cherubini E, Zacchi P.

Nat Commun. 2014 Oct 9;5:5066. doi: 10.1038/ncomms6066.

36.

Cooperation of p53 mutations with other oncogenic alterations in cancer.

Girardini JE, Walerych D, Del Sal G.

Subcell Biochem. 2014;85:41-70. doi: 10.1007/978-94-017-9211-0_3. Review.

PMID:
25201188
37.

Regulation of mitochondrial apoptosis by Pin1 in cancer and neurodegeneration.

Sorrentino G, Comel A, Mantovani F, Del Sal G.

Mitochondrion. 2014 Nov;19 Pt A:88-96. doi: 10.1016/j.mito.2014.08.003. Epub 2014 Aug 15. Review.

PMID:
25132079
38.

Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: insights in patients with diabetes.

Paneni F, Costantino S, Castello L, Battista R, Capretti G, Chiandotto S, D'Amario D, Scavone G, Villano A, Rustighi A, Crea F, Pitocco D, Lanza G, Volpe M, Del Sal G, Lüscher TF, Cosentino F.

Eur Heart J. 2015 Apr 1;36(13):817-28. doi: 10.1093/eurheartj/ehu179. Epub 2014 May 5.

39.

The cytoplasmic side of p53's oncosuppressive activities.

Comel A, Sorrentino G, Capaci V, Del Sal G.

FEBS Lett. 2014 Aug 19;588(16):2600-9. doi: 10.1016/j.febslet.2014.04.015. Epub 2014 Apr 18. Review.

40.

Metabolic control of YAP and TAZ by the mevalonate pathway.

Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio R, Piazza S, Rosato A, Piccolo S, Del Sal G.

Nat Cell Biol. 2014 Apr;16(4):357-66. doi: 10.1038/ncb2936. Epub 2014 Mar 23.

PMID:
24658687
41.

DLX5, FGF8 and the Pin1 isomerase control ΔNp63α protein stability during limb development: a regulatory loop at the basis of the SHFM and EEC congenital malformations.

Restelli M, Lopardo T, Lo Iacono N, Garaffo G, Conte D, Rustighi A, Napoli M, Del Sal G, Perez-Morga D, Costanzo A, Merlo GR, Guerrini L.

Hum Mol Genet. 2014 Jul 15;23(14):3830-42. doi: 10.1093/hmg/ddu096. Epub 2014 Feb 25.

42.

Immunohistochemical Characterization of a Renal Nephroblastoma in a Trp53-mutant and Prolyl Isomerase 1-deficient Mouse.

Castiglioni V, De Maglie M, Queliti R, Rustighi A, Del Sal G, Radaelli E.

J Toxicol Pathol. 2013 Dec;26(4):423-7. doi: 10.1293/tox.2013-0021. Epub 2013 Dec 26.

43.

Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast.

Rustighi A, Zannini A, Tiberi L, Sommaggio R, Piazza S, Sorrentino G, Nuzzo S, Tuscano A, Eterno V, Benvenuti F, Santarpia L, Aifantis I, Rosato A, Bicciato S, Zambelli A, Del Sal G.

EMBO Mol Med. 2014 Jan;6(1):99-119. doi: 10.1002/emmm.201302909. Epub 2013 Dec 15. Erratum in: EMBO Mol Med. 2014 May;6(5):702.

44.

Prolyl isomerase Pin1 and protein kinase HIPK2 cooperate to promote cortical neurogenesis by suppressing Groucho/TLE:Hes1-mediated inhibition of neuronal differentiation.

Ciarapica R, Methot L, Tang Y, Lo R, Dali R, Buscarlet M, Locatelli F, del Sal G, Rota R, Stifani S.

Cell Death Differ. 2014 Feb;21(2):321-32. doi: 10.1038/cdd.2013.160. Epub 2013 Nov 22.

45.

Disarming mutant p53 oncogenic function.

Girardini JE, Marotta C, Del Sal G.

Pharmacol Res. 2014 Jan;79:75-87. doi: 10.1016/j.phrs.2013.11.003. Epub 2013 Nov 15.

PMID:
24246451
46.

Autophosphorylation and Pin1 binding coordinate DNA damage-induced HIPK2 activation and cell death.

Bitomsky N, Conrad E, Moritz C, Polonio-Vallon T, Sombroek D, Schultheiss K, Glas C, Greiner V, Herbel C, Mantovani F, del Sal G, Peri F, Hofmann TG.

Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):E4203-12. doi: 10.1073/pnas.1310001110. Epub 2013 Oct 21.

47.

HIV-1 integrase binding to its cellular partners: a perspective from computational biology.

Quy VC, Carnevale V, Manganaro L, Lusic M, Rossetti G, Leone V, Fenollar-Ferrer C, Raugei S, Del Sal G, Giacca M, Carloni P.

Curr Pharm Des. 2014;20(21):3412-21. Review.

PMID:
24001231
48.

HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness.

Pegoraro S, Ros G, Piazza S, Sommaggio R, Ciani Y, Rosato A, Sgarra R, Del Sal G, Manfioletti G.

Oncotarget. 2013 Aug;4(8):1293-308.

49.

Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer.

Bisso A, Faleschini M, Zampa F, Capaci V, De Santa J, Santarpia L, Piazza S, Cappelletti V, Daidone M, Agami R, Del Sal G.

Cell Cycle. 2013 Jun 1;12(11):1679-87. doi: 10.4161/cc.24757. Epub 2013 May 1.

50.

Prolyl isomerase PIN1 regulates DNA double-strand break repair by counteracting DNA end resection.

Steger M, Murina O, Hühn D, Ferretti LP, Walser R, Hänggi K, Lafranchi L, Neugebauer C, Paliwal S, Janscak P, Gerrits B, Del Sal G, Zerbe O, Sartori AA.

Mol Cell. 2013 May 9;50(3):333-43. doi: 10.1016/j.molcel.2013.03.023. Epub 2013 Apr 25.

Supplemental Content

Loading ...
Support Center